Nfluence of tianeptine on melatonin homeostasis and psychosomatic symptoms in patients with irritable bowel syndrome

Journal of Physiology and Pharmacology

Volumn 64, Issue 2, 2013, Pages

  Chojnacki, C ^a   Walecka Kapica, E ^a   Mokwinska, M ^a   Romanowski, M ^a   Pawlowicz, M ^a   Chojnacki, J ^a   Klupinska, G ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

6 Sulfatoxymelatonin; Irritable bowel syndrome; Melatonin; Psychosomatic symptoms; Tianeptine

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; MELATONIN; PLACEBO; TIANEPTINE; 6-SULFATOXYMELATONIN; SEROTONIN UPTAKE INHIBITOR; THIAZEPINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HORMONE METABOLISM; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PSYCHOSOMATIC DISORDER; QUALITY OF LIFE; URINE LEVEL; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; HOMEOSTASIS; IRRITABLE BOWEL SYNDROME; METABOLISM; MIDDLE AGED; PSYCHOLOGY; URINE; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; FEMALE; HOMEOSTASIS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MELATONIN; MIDDLE AGED; PSYCHOPHYSIOLOGIC DISORDERS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; THIAZEPINES; YOUNG ADULT;

EID: 84891674499     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Choung RS, Locke GR. Epidemiology of IBS. Gastroenterol Clin North Am 2011; 40: 1-10.
2. Talley NJ. Irritabile bowel syndrome. Intern Med J 2006; 36: 724-728.
3. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381-396.
4. Mulak A, Bonaz B. Irritable bowel syndrome: a model of the brain-gut interactions. Med Sci Monit 2004; 10: 55-62.
5. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 2011; 62: 139-150.
6. Jones MP, Dilley JB, Drossman D, Crowell MD. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91-103.
7. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011; 62: 591-599.
8. Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001; 62(Suppl 8): 38-45.
9. Castle MZ, Silk DB, Libby GW. The rationale for antidepressant therapy in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 19: 969-979.
10. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
11. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378.
12. Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41: 854-862.
13. Grover M, Drossman DA. Centrally acting therapies for irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 183-206.
14. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738-741.
15. Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 678-684.
16. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54: 601-607.
17. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-748.
18. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 159-166.
19. Bixquert-Jimenez M, Bixquert-Pla L. Antidepressant therapy in functional gastrointestinal disorders. Gastroenterol Hepatol 2005; 28: 485-492.
20. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005; 22: 381-385.
21. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43.
22. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-928.
23. Siproudhis L, Dinasquet M, Sebille V, Reymann JM, Bellissant E. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception. Aliment Pharmacol Ther 2004; 20: 689-695.
24. Pacher P, Ungvari Z, Kecskemeti V, Friedmann T, Furst S. Serotonin reuptake inhibitors fluoxetine and citalopram relax intestinal smooth muscle. Can J Physiol Pharmacol 2001; 79: 580-584.
25. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357.
26. Pierpaoli W, Regelson W. The melatonin miracle. New York, Simon and Schuster, 1996.
27. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129-1146.
28. Brzozowski T, Konturek PC, Konturek SJ, et al. The role of melatonin and L-tryptophan in prevention of acute gastric lesions induced by stress, ethanol, ischemia, and aspirin. J Pineal Res 1997; 23: 79-89.
29. Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis 2009; 15: 134-140.
30. Bubenik GA. The effect of serotonin, N-acetylserotonin, and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res 1986; 3: 41-54.
31. Harlow HJ, Weekley BL. Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. J Pineal Res 1986; 3: 277-284.
32. Reyes-Vazquez C, Naranjo-Rodriguez EB, Garcia-Segoviano JA, Trujillo-Santana JT, Prieto-Gomez B. Apamin blocks the direct relaxant effect of melatonin on rat ileal smooth muscle. J Pineal Res 1997; 22: 1-8.
33. Kasimay O, Cakir B, Devseren E, Yegen BC. Exogenous melatonin delays gastric emptying rate in rats: role of CCK2 and 5-HT3 receptors. J Physiol Pharmacol 2005; 56: 543-553.
34. Pozo MJ, Gomez-Pinilla PJ, Camello-Almaraz C, et al. Melatonin, a potential therapeutic agent for smooth muscle-related pathological conditions and aging. Curr Med Chem 2010; 17: 4150-4165.
35. Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 2011; 17: 3888-3898.
36. Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006; 21(Suppl 1): 17-20.
37. Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009; 18: 1533-1540.
38. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005; 22: 927-934.
39. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-1407.
40. Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32.
41. Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Curr Pharm Des 2010; 16: 3646-3655.
42. Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discov 2006; 1: 29-41.
43. Kasper S, Olié JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 2002; 17(Suppl 3): 331-340.
44. Wilde MI, Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 1995; 49: 411-439.
45. Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders. CNS Drugs 2001; 15: 231-259.
46. Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22: 15-26.
47. Kato G, Weitsch AF. Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol 1988; 11(Suppl 2): 43-50.
48. Lechin F, van der Dijs B, Hernandez G, Orozco B, Rodriguez S, Baez S. Acute effects of tianeptine on circulating neurotransmitters and cardiovascular parameters. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 214-222.
49. Delbende C, Tranchand Bunel D, Tarozzo G, et al. Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis. Eur J Pharmacol 1994; 251: 245-251.
50. McEwen BS, Chattarji S, Diamond DM, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15: 237-249.
51. Uzbay TI. Tianeptine: potential influences on neuroplasticity and novel pharmacological effects. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 915-924.
52. McEwen BS, Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur Neuropsychopharmacol 2004; 14(Suppl 5): 497-502.
53. Vukovic O, Maric NP, Britvic D, et al. Efficacy, tolerability and safety of tianeptine in special populations of depressive patients. Psychiatr Danub 2009; 21: 194-198.
54. Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, Klupinska G, Jaworek J, Chojnacki J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 2011; 62: 327-334.
55. Chojnacki C, Walecka-Kapica E, Klupinska G, Pawlowicz M, et al. Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission. Pol Merkur Lekarski 2011; 31: 92-96.
56. Sohn W, Lee OY, Kwon JG, et al. Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Neurogastroenterol Motil 2012; 24: 860-398.
57. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166-1173.
58. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998; 24: 58-61.
59. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659.
60. Bolton VN, Bassil AK, Lee K, Sanger GJ. Inhibition by tianeptine of neuronally mediated contractions in the rat isolated gastrointestinal tract. Pharmacol Res 2008; 57: 339-343.
61. Lechin F, van der Dijs B, Lechin AE. Treatment of bronchial asthma with tianeptine. Methods Find Exp Clin Pharmacol 2004; 26: 697-701.
62. Suleyman H, Cadirci E, Albayrak A, Polat B, et al. Comparative study on the gastroprotective potential of some antidepressants in indomethacin-induced ulcer in rats. Chem Biol Interact 2009; 180: 318-324.